Longitudinal Findings from a Randomized Clinical Trial of Varenicline for Alcohol Use Disorder with Comorbid Cigarette Smoking
Longitudinal Findings from a Randomized Clinical Trial of Varenicline for Alcohol Use Disorder with Comorbid Cigarette Smoking
复制标题
DOI：
10.1111/acer.13994
复制
发表时间：
2019-05-01
影响因子：
3.2
通讯作者：
O'Malley, Stephanie S.
中科院分区：
文献类型：
--
作者：
Bold, Krysten W.;Zweben, Allen;O'Malley, Stephanie S.
本研究首次对伐尼克兰治疗酒精使用障碍（AUD）合并吸烟的安慰剂对照试验的纵向治疗后结果进行了研究。方法在随机、双盲、平行、安慰剂对照、16周的多地点试验中，131名寻求酒精治疗的成年人（n=39名女性）接受伐尼克兰联合药物治疗（MM）。在治疗结束时（4个月）对酒精和吸烟行为进行时间线随访评估，并在6、9和12个月进行随访。结果是重度饮酒天数（PHDD）的百分比，无重度饮酒天数（NHDD）的百分比，可替宁证实的长期戒烟（PA），以及NHDD或PA的良好临床结果。结果治疗后治疗效果保持良好。总体而言，PHDD或NHDD在治疗条件下没有显着差异（ps>0.13），但伐尼克兰在4、9和12个月时比安慰剂产生更高的PA率(p
BackgroundThis study is the first to examine longitudinal posttreatment outcomes of a placebo-controlled trial of varenicline for alcohol use disorder (AUD) with comorbid cigarette smoking.MethodsParticipants were 131 adults (n=39 female) seeking alcohol treatment in a randomized, double-blind, parallel group, placebo-controlled, 16-week multisite trial of varenicline combined with medical management (MM). Timeline follow-back assessments of alcohol and smoking behavior were conducted at the end of treatment (4months), with follow-ups at 6, 9, and 12months. Outcomes were percentage of heavy drinking days (PHDD), percent of participants with no heavy drinking days (NHDD), cotinine-confirmed prolonged smoking abstinence (PA), and good clinical outcome on either NHDD or PA.ResultsTreatment improvements were maintained posttreatment. For the sample overall, PHDD or NHDD did not differ significantly by treatment condition (ps>0.13), but varenicline produced higher rates of PA versus placebo at 4, 9, and 12months (p